Z-206 ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	3
97	Ulcerative colitis	4

96. Crohn disease

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-C000000301	2005/12/01	22/12/2005	Z-206Phase III Clinical Trial-Investigation on the remission–maintaining effect in patients with Cro ...		Patients with Crohn's disease in remission phase	Z-206group:Three tablets of Z-206400mg tablet, 4 tablets of Pentasa placebo tablet per time (total 7 ...	Zeria Pharmaceutical Co.,LTD.	NULL	Complete: follow-up complete	16years-old	64years-old	Male and Female	40	Phase 2,3	Japan
2	JPRN-C000000300	2005/12/01	22/12/2005	Z-206Phase III Clinical Trial- Investigation on the remission-inducing effect in patients with Crohn ...		Patients with Crohn's disease in active phase	Z-206group:Three tablets of Z-206400mg tablet, 4 tablets of Pentasa placebo tablet per time (total 7 ...	Zeria Pharmaceutical Co.,LTD	NULL	Complete: follow-up complete	16years-old	64years-old	Male and Female	60	Phase 3	Japan
3	JPRN-JapicCTI-111460		29/03/2011	Phase II Study of Z-206 in Patients with Active Crohn's Disease	Phase II Study of Z-206 in Patients with Active Crohn's Disease	Active Crohn's disease	Intervention name : Z-206 INN of the intervention : Mesalazine Dosage And administration of the interv ...	Zeria Pharmaceutical Co., Ltd.	Kyowa Hakko Kirin Co., Ltd.		16	64	BOTH		Phase 2	NULL

First Previous1Next Last

97. Ulcerative colitis

Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-132135	01/5/2013		Phase III Study of Z-206	Phase III Study of Z-206	Ulcerative Colitis	Intervention name : Z-206 INN of the intervention : Mesalazine Dosage And administration of the interv ...	Zeria Pharmaceutical Co., Ltd.	Kyowa Hakko Kirin Co., Ltd.		16	64	BOTH	600	Phase 3	NULL
2	JPRN-C000000289	2005/12/01	21/11/2005	Z-206Phase III Clinical Trial- Investigation on the remission-maintaining effect in patients with ul ...		Patients with ulcerative colitis in remission phase.	Z-206group : Two Z-206400 mg tablets, 3 tablets of Pentasa placebo tablet per time (total 5 tablets) ...	Zeria Pharmaceutical Co.,LTD.	NULL	Complete: follow-up complete	16years-old	64years-old	Male and Female	120	Phase 3	Japan
3	JPRN-C000000288	2005/12/01	21/11/2005	Z-206Phase III Clinical Trial- Investigation on the remission-inducing effect in patients with ulcer ...		Patients with ulcerative colitis in active phase	Z-2062.4g/day dose group: Two Z-206400mg tablets, 1 tablet of Z-206placebo tablet, 3 tablets of Pent ...	Zeria Pharmaceutical Co.,LTD.	NULL	Complete: follow-up complete	16years-old	64years-old	Male and Female	210	Phase 3	Japan
4	JPRN-JapicCTI-121943		30/08/2012	Phase II Study of Z-206	Phase II Study of Z-206	Ulcerative colitis	Intervention name : Z-206 INN of the intervention : Mesalazine Dosage And administration of the interv ...	Zeria Pharmaceutical Co., Ltd.	Kyowa Hakko Kirin Co., Ltd.				BOTH		Phase 2	NULL

First Previous1Next Last